ZRANB2 and SYF2 mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin

We explored the regulation of alternative splicing in a cell model of breast cancer resistance to doxorubicin, and the impact of the depletion of two splicing factors (ZRANB2 and SYF2) in this context. Overall design: We analyzed by RNA-seq, alternative splicing regulation between doxorubicin-resistant and sensitive cells, and between resistant cells with ot without depletion of either ZRANB2 or SYF2 (2 independent siRNAs for each, all conditions in triplicate).